ICAM1 and cutaneous mastocytosis: This study therefore highlights stronger endothelial adhesion capacity to both ICAM-1 and EPCR as a risk factor for development of CM and identifies a group of PfEMP1s with a remarkably conserved ICAM-1-binding site as potential vaccine immunogen for use as part of a strategy to prevent death due to CM.